<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Homoharringtonine (HHT), a natural <z:chebi fb="13" ids="22315">alkaloid</z:chebi> extracted from various Cephalotaxus species, exerts its antitumoral and anti-angiogenic activity through an inhibition of protein synthesis and the promotion of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="1" pm="."><plain>ChemGenex Pharmaceuticals Ltd, in collaboration with Stragen Group, is developing omacetaxine mepesuccinate, a semisynthetic formulation of HHT, as a potential treatment for <z:hpo ids='HP_0011010'>chronic</z:hpo> myelocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:mp ids='MP_0005481'>CML</z:mp>), <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>In preclinical studies, omacetaxine mepesuccinate induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in <z:hpo ids='HP_0001909'>leukemia</z:hpo> cell lines </plain></SENT>
<SENT sid="3" pm="."><plain>Results from phase II clinical trials revealed omacetaxine mepesuccinate to be active in patients with <z:mp ids='MP_0005481'>CML</z:mp> that was resistant to <z:chebi fb="0" ids="38637">tyrosine kinase inhibitor</z:chebi> (TKI) therapy, including those patients who carry the BCR-ABL1T315I mutation, which is highly insensitive to the TKIs <z:chebi fb="0" ids="45783">imatinib</z:chebi>, <z:chebi fb="0" ids="52172">nilotinib</z:chebi> and <z:chebi fb="0" ids="49375">dasatinib</z:chebi>; the therapeutic was also generally well tolerated </plain></SENT>
<SENT sid="4" pm="."><plain>Phase II and III clinical trials are underway to assess the activity of omacetaxine mepesuccinate, either alone or in combination with TKIs or other cytotoxic drugs, in patients with <z:mp ids='MP_0005481'>CML</z:mp> that is resistant to TKI therapy </plain></SENT>
<SENT sid="5" pm="."><plain>Phase I and II clinical trials for omacetaxine mepesuccinate in the treatment of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> are also ongoing; intravenous, subcutaneous and oral formulations of the drug are being developed </plain></SENT>
<SENT sid="6" pm="."><plain>Omacetaxine mepesuccinate appears to hold potential for the treatment of <z:mp ids='MP_0005481'>CML</z:mp> and, in particular, <z:chebi fb="0" ids="45783">imatinib</z:chebi>-resistant <z:mp ids='MP_0005481'>CML</z:mp>; the development of alternative formulations of the therapeutic further expands the potential for success in drug development </plain></SENT>
</text></document>